Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibition and kidney protection
Josselin Nespoux, Volker Vallon
Clinical Science (2018) Vol. 132, Iss. 12, pp. 1329-1339
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

The tubular hypothesis of nephron filtration and diabetic kidney disease
Volker Vallon, Scott C. Thomson
Nature Reviews Nephrology (2020) Vol. 16, Iss. 6, pp. 317-336
Open Access | Times Cited: 324
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Lucas Opazo-Ríos, Sebastián Mas, Gema Marín‐Royo, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2632-2632
Open Access | Times Cited: 248
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Jana Bláhová, Monika Martiniaková, Martina Babikova, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 806-806
Open Access | Times Cited: 187
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca‐Correa, Ricardo Correa‐Rotter
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 153
The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Anne C. Hesp, Jennifer A. Schaub, Pottumarthi V. Prasad, et al.
Kidney International (2020) Vol. 98, Iss. 3, pp. 579-589
Open Access | Times Cited: 145
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Jing Yang, Zhangsuo Liu
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 143
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Sankar D. Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, et al.
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 17
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
Jonatan Barrera‐Chimal, Frédéric Jaisser
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 16-31
Open Access | Times Cited: 129
Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease
Sijie Chen, Lin‐Li Lv, Bi‐Cheng Liu, et al.
Cell Proliferation (2020) Vol. 53, Iss. 3
Open Access | Times Cited: 105
Renal effects of SGLT2 inhibitors
Josselin Nespoux, Volker Vallon
Current Opinion in Nephrology & Hypertension (2019) Vol. 29, Iss. 2, pp. 190-198
Open Access | Times Cited: 103
Glucose transporters in the kidney in health and disease
Volker Vallon
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 9, pp. 1345-1370
Open Access | Times Cited: 102
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials
Husam M. Salah, Subhi J. Al’Aref, Muhammad Shahzeb Khan, et al.
American Heart Journal (2020) Vol. 232, pp. 10-22
Closed Access | Times Cited: 98
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
Anton I. Korbut, Iuliia Taskaeva, Н. П. Бгатова, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2987-2987
Open Access | Times Cited: 88
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 86
Drug Delivery System in the Treatment of Diabetes Mellitus
Ruichen Zhao, Zhiguo Lü, Jun Yang, et al.
Frontiers in Bioengineering and Biotechnology (2020) Vol. 8
Open Access | Times Cited: 83
Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment
Sameer P. Leley, Thomas A. Ciulla, Ashay D. Bhatwadekar
Clinical Interventions in Aging (2021) Vol. Volume 16, pp. 1367-1378
Open Access | Times Cited: 69
Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure
Flávio A. Borges-Júnior, Danúbia Silva dos Santos, Acaris Benetti, et al.
Journal of the American Society of Nephrology (2021) Vol. 32, Iss. 7, pp. 1616-1629
Open Access | Times Cited: 66
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Sreenithya Ravindran, Shankar Munusamy
Journal of Cellular Physiology (2021) Vol. 237, Iss. 2, pp. 1182-1205
Closed Access | Times Cited: 61
Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs
Meihui Wang, Zixu Wang, Yaoxing Chen, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 747-747
Open Access | Times Cited: 52
Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
Xin Chen, Carl‐Friedrich Hocher, Linghong Shen, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 3, pp. C661-C681
Closed Access | Times Cited: 32
Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
Xin Chen, Denis Delić, Yaochen Cao, et al.
AJP Cell Physiology (2023) Vol. 324, Iss. 4, pp. C951-C962
Open Access | Times Cited: 31
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Rong Cao, Huimin Tian, Yu Zhang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Giovanna Gallo, Massimo Volpe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2484-2484
Open Access | Times Cited: 10
Renal physiology of glucose handling and therapeutic implications
David Z.I. Cherney, Mehmet Kanbay, Julie A. Lovshin
Nephrology Dialysis Transplantation (2019) Vol. 35, Iss. Supplement_1, pp. i3-i12
Open Access | Times Cited: 56
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Roko Škrabić, Marko Kumrić, Josip Vrdoljak, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2458-2458
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top